 Aquestive Therapeutics has been making deals to generate cash to help develop their epinephrine candidate, AQST-109. Aquestive appears to be going all-in on AQST-109s clinical and commercial success. I intend to provide a brief background on AQST-109 and will review the companys efforts to prioritize its development. 